Fibrates in the management of atherogenic dyslipidemia

Expert Rev Cardiovasc Ther. 2017 Dec;15(12):913-921. doi: 10.1080/14779072.2017.1408410. Epub 2017 Nov 28.

Abstract

Significant advancements in the treatment of hypercholesterolemia have recently been achieved. However, a considerable level of residual cardiovascular risk still affects patients' outcomes. Atherogenic dyslipidemia is one of the major constituents of residual risk. Fibrates, PPAR alpha agonists, which modify lipid profile and have numerous pleiotropic effects, seem to be drugs of choice in patients with atherogenic dyslipidemia. These drugs are effective both in monotherapy and combined therapy with statins. Areas covered: A review of clinical trials and experimental studies on fibrates and their use in the treatment of lipid disorders has been performed. Expert commentary: Fibrates are an effective and safe group of drugs to treat patients with atherogenic dyslipidemia. In this particular population of patients, they improve cardiovascular outcomes. Benefits of fibrate treatment extend beyond the impact of lipid profile. Significant improvements in carbohydrate metabolism, adipokines levels, thrombosis and inflammation were also noted.

Keywords: Fibrates; HDL-cholesterol; PPAR alpha; atherogenic dyslipidemia; triglycerides.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / complications
  • Atherosclerosis / drug therapy*
  • Dyslipidemias / complications
  • Dyslipidemias / drug therapy*
  • Female
  • Fibric Acids / therapeutic use*
  • Humans
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood
  • Male
  • Risk Factors

Substances

  • Fibric Acids
  • Hypolipidemic Agents
  • Lipids